Alere's revenue soars; MRI Global to develop anthrax blood Dx

> Alere ($ALR) said it generated nearly $754 million in revenue during the 2013 third quarter, an increase due, in part, to healthy gains in diagnostics sales. But the Massachusetts company lost $24.8 million. Release

> LabCorp ($LH) said it expects to refinance some debt and plans to issue senior notes in two tranches that will mature in 5 and 10 years, respectively. Item

> Researchers believe they've come up with a blood test that could predict a baby's genetic risk of diabetes from birth. Story (sub. req.)

> Enzo Biochem ($ENZ) said it will market Sequenom's ($SQNM) early noninvasive prenatal laboratory test service in the northeast U.S. Item

> Seattle's Indi, or Integrated Diagnostics, unveiled a protein expression blood test this week designed to help determine if lung nodules found during early screening are benign and don't need to be taken out. Story

> MRI Global has a $1.6 million contract from the U.S. Department of Health and Human Services to develop a quick blood test for anthrax detection if a chemical attack hits. Item